Company / Working Capital
Krystal Biotech, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$921.7M
FY2025
5-year range
$354.9M / $921.7M
FY2021-FY2025
Trend
+44.0%
vs FY2024
Sector context
#43 of 213
Health Care
What the data says
Krystal Biotech, Inc.'s working capital of $922M is higher than 80% of companies in the Health Care sector (FY2025). Working Capital has increased for 3 consecutive years, from $355M in FY2022 to $922M in FY2025.
Based on SEC 10-K filings.
$922M in FY2025 with a 5-year CAGR of +28.8%. Top quartile in the Health Care sector.
Improved from $555M to $922M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +37.4%
- 5-Year CAGR
- +28.8%
- 10-Year CAGR
- -
Sector benchmark
-1.4% below sector average
Key checks
Key Insights
- Krystal Biotech, Inc.'s working capital has grown for 3 consecutive years.
- 5-year CAGR of +28.8%, indicating consistent growth.
- In FY2025, working capital increased 44.0% year-over-year.
- Ranks #43 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 5.66 (safe zone, above 2.9 threshold)
- Strong profit margin: 30.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $921.7M | +44.0% |
| FY2024 | $640.0M | +15.4% |
| FY2023 | $554.8M | +56.3% |
| FY2022 | $354.9M | -14.8% |
| FY2021 | $416.5M | +60.4% |
| FY2020 | $259.6M | +34.8% |
| FY2019 | $192.6M | +75.0% |
| FY2018 | $110.1M | +123.4% |
| FY2017 | $49.3M | +2217.7% |
| FY2016 | $2.1M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026